After screening nearly 40,000 compounds, an experimental inhibitor slowed pancreatic tumor growth, improved survival, and enhanced gemcitabine in preclinical studies. More studies are needed before testing in people. doi.org/hcdr4v
First-in-class small molecule inhibitor shows promise against pancreatic cancer in preclinical studies
Mayo Clinic researchers have developed an experimental drug with the help of artificial intelligence (AI) to target the "undruggable" PDZ domain of the GIPC1 protein, which helps different types of cancer, including pancreatic cancer, grow and resist treatment.
medicalxpress.com